Dr Pietro Canetta reflects on how the rapidly advancing field of IgA nephropathy research has transformed from limited ...

Dr Andrew Bomback comments on how disparities in access to healthcare significantly delay the diagnosis and treatment of IgA ...

Immunoglobulin A (IgA) nephropathy, also called Berger’s disease, is an autoimmune disease that affects your kidneys. IgA is an antibody. Antibodies are proteins made by your immune system.

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

IgA nephropathy is an autoimmune disease of the kidneys. It’s associated with several health conditions and is a significant contributor to chronic kidney disease and kidney failure. In the ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...